Breaking News: Item 9 Labs Corp Broadens National Footprint Announces Joint Venture With Strive Wellness of Nevada | Financial Buzz

Breaking News: Item 9 Labs Corp Broadens National Footprint Announces Joint Venture With Strive Wellness of Nevada

Arizona-based Item 9 Labs Corp. (OTC: INLB) (Item 9 Labs or the Company), today announced a joint venture with Strive Wellness of Nevada, LLC (Strive Wellness), to construct and manage the 20,000 square-foot medical marijuana cultivation and processing facility in Pahrump, Nevada.

Strive Wellness was approved for a medical marijuana license in April and received its Special Use Permit (SUP) in December 2018The facility will implement sustainable construction practices suggested by Bowden Investment Group, a company specializing in real estate and environmentally friendly development. Strive Wellness is estimated to be producing legal medical marijuana products in the next nine months.

“This joint venture opens up new territory for growth in a larger medical marijuana market, bolstered further by its reciprocity laws,” stated Sara Gullickson, CEO of Item 9 Labs. “This new facility will double our overall capacity and productivity by an additional 20,000 square-feet. We plan to break ground in February and begin producing legal medical marijuana products in September 2019.”

It was important for Item 9 Labs to be involved in Nevada’s medical marijuana program as the Company broadens its national footprint. Nevada is one of the few states that recognizes reciprocity, allowing out-of-state medical marijuana cardholders to legally purchase when visiting. In addition, Item 9 Labs is prepared to anticipate market needs and fluctuations. “When adult-use sales spike, we want to ensure patients still have access to high-grade medicinal marijuana product. We expect to make a major impact with our organic practices and premium flower and concentrates,” explained Gullickson.

According to analytics firm New Frontier, the Nevada medical marijuana program reached peak registration in Fall 2018 with 25,600 patients, a conservative number not factoring in reciprocity patients. Nevada’s legal market is estimated to be worth $622 million by 2020, a feat attributed to the global appeal of Las Vegas as a tourist destination.

The Strive Wellness site is strategically located an hour from Las Vegas and five hours from Los Angeles and Phoenix. Item 9 Labs currently operates an indoor cultivation facility zoned on 50 acres in Arizona and is a leading developer and manufacturer of innovative marijuana products and proprietary delivery platforms.
For information visit

Sponsored Content Release. Click for Full Disclosure

  • Sponsored Content Release, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For item 9 labs corp. financial news dissemination and PR services, has been compensated five thousand dollars by axiom group. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: